In mid-May, OpenAI announced that an internal AI model had disproved the Erdős unit distance conjecture, a famous problem in ...

Katelyn is a reporter with CNET covering artificial intelligence, including chatbots, image and video generators. Her work explores how new AI technology is infiltrating our lives, shaping the content ...

In this post, we will show you how to create email templates in the new Outlook app for Windows 11. Creating email or message templates in Microsoft Outlook (classic) involved manually composing an ...

If you've ever wanted to integrate OpenAI's ChatGPT features into your Java programs, you'll be happy to learn that Spring AI has made the process easier than ever. And it's not just easier to connect ...

Here's the revised video description with all the links and additional text removed: --- Learn how to graph quadratics in standard form. A quadratic equation is an equation whose highest exponent in ...

Waterloo scientists have developed a new way to understand how the universe began, and it could change what we know about the Big Bang and the earliest moments of cosmic history. Their work suggests ...

OpenAI is rolling out new interactive responses in ChatGPT it says are designed to make the chatbot more useful for learners. Starting today, ChatGPT will generate dynamic visuals when you ask it to ...

If you're stumped by an abstract math problem or a complicated physics concept, ChatGPT can help. Announced today, OpenAI's chatbot can now generate interactive visuals in response to prompts on math ...

Feb 23 (Reuters) - Drug developer Generate Biomedicines said on Monday it was targeting a valuation of up to $2.17 billion in its U.S. initial public offering, tapping into a resurgent biotech market ...

Generate Biomedicines Inc., a biotechnology firm using artificial intelligence in drug development, is seeking to raise as much as $425 millon in an initial public offering, as listing activity in the ...

Generate Biomedicines, Inc. (GENB) has filed to raise public capital in an IPO to advance its pipeline of treatment candidates, according to an SEC filing. The company is developing treatments for ...